The global market for Antibody Drug Conjugate CDMO was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Antibody-Drug Conjugate (ADC) is a type of targeted cancer therapy that utilizes monoclonal antibodies to deliver cytotoxic drugs directly to cancer cells, minimizing damage to healthy cells. ADCs have shown promising results in treating various types of cancers.A Contract Development and Manufacturing Organization (CDMO) specializes in providing services related to the development, manufacturing, and testing of pharmaceuticals, including biologics like ADCs.

North American market for Antibody Drug Conjugate CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Antibody Drug Conjugate CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global market for Antibody Drug Conjugate CDMO in Solid Tumors is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Antibody Drug Conjugate CDMO include Lonza Group, Merck KGaA, Recipharm, Thermo Fisher Scientific, Abbvie, Piramal Pharma Solutions, Catalent, Sterling Pharma Solutions, Curia, Novasep, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Antibody Drug Conjugate CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody Drug Conjugate CDMO.

The Antibody Drug Conjugate CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antibody Drug Conjugate CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Antibody Drug Conjugate CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Antibody Drug Conjugate CDMO Market Report

Report Metric	Details
Report Name	Antibody Drug Conjugate CDMO Market
Segment by Type	IgG1 IgG4
Segment by Application	Solid Tumors Hematological Malignancies
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Lonza Group, Merck KGaA, Recipharm, Thermo Fisher Scientific, Abbvie, Piramal Pharma Solutions, Catalent, Sterling Pharma Solutions, Curia, Novasep, Ajinomoto Bio-Pharma Services, BSP Pharmaceuticals, Cerbios-Pharma, Goodwin Biotechnology
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody Drug Conjugate CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Antibody Drug Conjugate CDMO Market report?

Ans: The main players in the Antibody Drug Conjugate CDMO Market are Lonza Group, Merck KGaA, Recipharm, Thermo Fisher Scientific, Abbvie, Piramal Pharma Solutions, Catalent, Sterling Pharma Solutions, Curia, Novasep, Ajinomoto Bio-Pharma Services, BSP Pharmaceuticals, Cerbios-Pharma, Goodwin Biotechnology

What are the Application segmentation covered in the Antibody Drug Conjugate CDMO Market report?

Ans: The Applications covered in the Antibody Drug Conjugate CDMO Market report are Solid Tumors, Hematological Malignancies

What are the Type segmentation covered in the Antibody Drug Conjugate CDMO Market report?

Ans: The Types covered in the Antibody Drug Conjugate CDMO Market report are IgG1, IgG4

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Antibody Drug Conjugate CDMO Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 IgG1

1.2.3 IgG4

1.3 Market by Application

1.3.1 Global Antibody Drug Conjugate CDMO Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Solid Tumors

1.3.3 Hematological Malignancies

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Antibody Drug Conjugate CDMO Market Perspective (2020-2031)

2.2 Global Antibody Drug Conjugate CDMO Growth Trends by Region

2.2.1 Global Antibody Drug Conjugate CDMO Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Antibody Drug Conjugate CDMO Historic Market Size by Region (2020-2025)

2.2.3 Antibody Drug Conjugate CDMO Forecasted Market Size by Region (2026-2031)

2.3 Antibody Drug Conjugate CDMO Market Dynamics

2.3.1 Antibody Drug Conjugate CDMO Industry Trends

2.3.2 Antibody Drug Conjugate CDMO Market Drivers

2.3.3 Antibody Drug Conjugate CDMO Market Challenges

2.3.4 Antibody Drug Conjugate CDMO Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Antibody Drug Conjugate CDMO Players by Revenue

3.1.1 Global Top Antibody Drug Conjugate CDMO Players by Revenue (2020-2025)

3.1.2 Global Antibody Drug Conjugate CDMO Revenue Market Share by Players (2020-2025)

3.2 Global Antibody Drug Conjugate CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Antibody Drug Conjugate CDMO Revenue

3.4 Global Antibody Drug Conjugate CDMO Market Concentration Ratio

3.4.1 Global Antibody Drug Conjugate CDMO Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Antibody Drug Conjugate CDMO Revenue in 2024

3.5 Global Key Players of Antibody Drug Conjugate CDMO Head office and Area Served

3.6 Global Key Players of Antibody Drug Conjugate CDMO, Product and Application

3.7 Global Key Players of Antibody Drug Conjugate CDMO, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Antibody Drug Conjugate CDMO Breakdown Data by Type

4.1 Global Antibody Drug Conjugate CDMO Historic Market Size by Type (2020-2025)

4.2 Global Antibody Drug Conjugate CDMO Forecasted Market Size by Type (2026-2031)

5 Antibody Drug Conjugate CDMO Breakdown Data by Application

5.1 Global Antibody Drug Conjugate CDMO Historic Market Size by Application (2020-2025)

5.2 Global Antibody Drug Conjugate CDMO Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Antibody Drug Conjugate CDMO Market Size (2020-2031)

6.2 North America Antibody Drug Conjugate CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Antibody Drug Conjugate CDMO Market Size by Country (2020-2025)

6.4 North America Antibody Drug Conjugate CDMO Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Antibody Drug Conjugate CDMO Market Size (2020-2031)

7.2 Europe Antibody Drug Conjugate CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Antibody Drug Conjugate CDMO Market Size by Country (2020-2025)

7.4 Europe Antibody Drug Conjugate CDMO Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Antibody Drug Conjugate CDMO Market Size (2020-2031)

8.2 Asia-Pacific Antibody Drug Conjugate CDMO Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Antibody Drug Conjugate CDMO Market Size by Region (2020-2025)

8.4 Asia-Pacific Antibody Drug Conjugate CDMO Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Antibody Drug Conjugate CDMO Market Size (2020-2031)

9.2 Latin America Antibody Drug Conjugate CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Antibody Drug Conjugate CDMO Market Size by Country (2020-2025)

9.4 Latin America Antibody Drug Conjugate CDMO Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Antibody Drug Conjugate CDMO Market Size (2020-2031)

10.2 Middle East & Africa Antibody Drug Conjugate CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Antibody Drug Conjugate CDMO Market Size by Country (2020-2025)

10.4 Middle East & Africa Antibody Drug Conjugate CDMO Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Lonza Group

11.1.1 Lonza Group Company Details

11.1.2 Lonza Group Business Overview

11.1.3 Lonza Group Antibody Drug Conjugate CDMO Introduction

11.1.4 Lonza Group Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.1.5 Lonza Group Recent Development

11.2 Merck KGaA

11.2.1 Merck KGaA Company Details

11.2.2 Merck KGaA Business Overview

11.2.3 Merck KGaA Antibody Drug Conjugate CDMO Introduction

11.2.4 Merck KGaA Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.2.5 Merck KGaA Recent Development

11.3 Recipharm

11.3.1 Recipharm Company Details

11.3.2 Recipharm Business Overview

11.3.3 Recipharm Antibody Drug Conjugate CDMO Introduction

11.3.4 Recipharm Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.3.5 Recipharm Recent Development

11.4 Thermo Fisher Scientific

11.4.1 Thermo Fisher Scientific Company Details

11.4.2 Thermo Fisher Scientific Business Overview

11.4.3 Thermo Fisher Scientific Antibody Drug Conjugate CDMO Introduction

11.4.4 Thermo Fisher Scientific Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.4.5 Thermo Fisher Scientific Recent Development

11.5 Abbvie

11.5.1 Abbvie Company Details

11.5.2 Abbvie Business Overview

11.5.3 Abbvie Antibody Drug Conjugate CDMO Introduction

11.5.4 Abbvie Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.5.5 Abbvie Recent Development

11.6 Piramal Pharma Solutions

11.6.1 Piramal Pharma Solutions Company Details

11.6.2 Piramal Pharma Solutions Business Overview

11.6.3 Piramal Pharma Solutions Antibody Drug Conjugate CDMO Introduction

11.6.4 Piramal Pharma Solutions Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.6.5 Piramal Pharma Solutions Recent Development

11.7 Catalent

11.7.1 Catalent Company Details

11.7.2 Catalent Business Overview

11.7.3 Catalent Antibody Drug Conjugate CDMO Introduction

11.7.4 Catalent Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.7.5 Catalent Recent Development

11.8 Sterling Pharma Solutions

11.8.1 Sterling Pharma Solutions Company Details

11.8.2 Sterling Pharma Solutions Business Overview

11.8.3 Sterling Pharma Solutions Antibody Drug Conjugate CDMO Introduction

11.8.4 Sterling Pharma Solutions Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.8.5 Sterling Pharma Solutions Recent Development

11.9 Curia

11.9.1 Curia Company Details

11.9.2 Curia Business Overview

11.9.3 Curia Antibody Drug Conjugate CDMO Introduction

11.9.4 Curia Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.9.5 Curia Recent Development

11.10 Novasep

11.10.1 Novasep Company Details

11.10.2 Novasep Business Overview

11.10.3 Novasep Antibody Drug Conjugate CDMO Introduction

11.10.4 Novasep Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.10.5 Novasep Recent Development

11.11 Ajinomoto Bio-Pharma Services

11.11.1 Ajinomoto Bio-Pharma Services Company Details

11.11.2 Ajinomoto Bio-Pharma Services Business Overview

11.11.3 Ajinomoto Bio-Pharma Services Antibody Drug Conjugate CDMO Introduction

11.11.4 Ajinomoto Bio-Pharma Services Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.11.5 Ajinomoto Bio-Pharma Services Recent Development

11.12 BSP Pharmaceuticals

11.12.1 BSP Pharmaceuticals Company Details

11.12.2 BSP Pharmaceuticals Business Overview

11.12.3 BSP Pharmaceuticals Antibody Drug Conjugate CDMO Introduction

11.12.4 BSP Pharmaceuticals Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.12.5 BSP Pharmaceuticals Recent Development

11.13 Cerbios-Pharma

11.13.1 Cerbios-Pharma Company Details

11.13.2 Cerbios-Pharma Business Overview

11.13.3 Cerbios-Pharma Antibody Drug Conjugate CDMO Introduction

11.13.4 Cerbios-Pharma Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.13.5 Cerbios-Pharma Recent Development

11.14 Goodwin Biotechnology

11.14.1 Goodwin Biotechnology Company Details

11.14.2 Goodwin Biotechnology Business Overview

11.14.3 Goodwin Biotechnology Antibody Drug Conjugate CDMO Introduction

11.14.4 Goodwin Biotechnology Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)

11.14.5 Goodwin Biotechnology Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Lonza Group

Ajinomoto Bio-Pharma Services

BSP Pharmaceuticals

Merck KGaA

Recipharm

Thermo Fisher Scientific

AbbVie

Piramal Pharma Solutions

Catalent

Sterling Pharma Solutions

Curia

Novasep

Cerbios-Pharma

Goodwin Biotechnology

List of Tables

Table 1. Global Antibody Drug Conjugate CDMO Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of IgG1

Table 3. Key Players of IgG4

Table 4. Global Antibody Drug Conjugate CDMO Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global Antibody Drug Conjugate CDMO Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Antibody Drug Conjugate CDMO Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global Antibody Drug Conjugate CDMO Market Share by Region (2020-2025)

Table 8. Global Antibody Drug Conjugate CDMO Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global Antibody Drug Conjugate CDMO Market Share by Region (2026-2031)

Table 10. Antibody Drug Conjugate CDMO Market Trends

Table 11. Antibody Drug Conjugate CDMO Market Drivers

Table 12. Antibody Drug Conjugate CDMO Market Challenges

Table 13. Antibody Drug Conjugate CDMO Market Restraints

Table 14. Global Antibody Drug Conjugate CDMO Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Antibody Drug Conjugate CDMO Market Share by Players (2020-2025)

Table 16. Global Top Antibody Drug Conjugate CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody Drug Conjugate CDMO as of 2024)

Table 17. Ranking of Global Top Antibody Drug Conjugate CDMO Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by Antibody Drug Conjugate CDMO Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Antibody Drug Conjugate CDMO, Headquarters and Area Served

Table 20. Global Key Players of Antibody Drug Conjugate CDMO, Product and Application

Table 21. Global Key Players of Antibody Drug Conjugate CDMO, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Antibody Drug Conjugate CDMO Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Antibody Drug Conjugate CDMO Revenue Market Share by Type (2020-2025)

Table 25. Global Antibody Drug Conjugate CDMO Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Antibody Drug Conjugate CDMO Revenue Market Share by Type (2026-2031)

Table 27. Global Antibody Drug Conjugate CDMO Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global Antibody Drug Conjugate CDMO Revenue Market Share by Application (2020-2025)

Table 29. Global Antibody Drug Conjugate CDMO Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global Antibody Drug Conjugate CDMO Revenue Market Share by Application (2026-2031)

Table 31. North America Antibody Drug Conjugate CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America Antibody Drug Conjugate CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America Antibody Drug Conjugate CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe Antibody Drug Conjugate CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe Antibody Drug Conjugate CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe Antibody Drug Conjugate CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific Antibody Drug Conjugate CDMO Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific Antibody Drug Conjugate CDMO Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific Antibody Drug Conjugate CDMO Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America Antibody Drug Conjugate CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America Antibody Drug Conjugate CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America Antibody Drug Conjugate CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa Antibody Drug Conjugate CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa Antibody Drug Conjugate CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa Antibody Drug Conjugate CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 46. Lonza Group Company Details

Table 47. Lonza Group Business Overview

Table 48. Lonza Group Antibody Drug Conjugate CDMO Product

Table 49. Lonza Group Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 50. Lonza Group Recent Development

Table 51. Merck KGaA Company Details

Table 52. Merck KGaA Business Overview

Table 53. Merck KGaA Antibody Drug Conjugate CDMO Product

Table 54. Merck KGaA Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 55. Merck KGaA Recent Development

Table 56. Recipharm Company Details

Table 57. Recipharm Business Overview

Table 58. Recipharm Antibody Drug Conjugate CDMO Product

Table 59. Recipharm Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 60. Recipharm Recent Development

Table 61. Thermo Fisher Scientific Company Details

Table 62. Thermo Fisher Scientific Business Overview

Table 63. Thermo Fisher Scientific Antibody Drug Conjugate CDMO Product

Table 64. Thermo Fisher Scientific Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 65. Thermo Fisher Scientific Recent Development

Table 66. Abbvie Company Details

Table 67. Abbvie Business Overview

Table 68. Abbvie Antibody Drug Conjugate CDMO Product

Table 69. Abbvie Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 70. Abbvie Recent Development

Table 71. Piramal Pharma Solutions Company Details

Table 72. Piramal Pharma Solutions Business Overview

Table 73. Piramal Pharma Solutions Antibody Drug Conjugate CDMO Product

Table 74. Piramal Pharma Solutions Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 75. Piramal Pharma Solutions Recent Development

Table 76. Catalent Company Details

Table 77. Catalent Business Overview

Table 78. Catalent Antibody Drug Conjugate CDMO Product

Table 79. Catalent Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 80. Catalent Recent Development

Table 81. Sterling Pharma Solutions Company Details

Table 82. Sterling Pharma Solutions Business Overview

Table 83. Sterling Pharma Solutions Antibody Drug Conjugate CDMO Product

Table 84. Sterling Pharma Solutions Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 85. Sterling Pharma Solutions Recent Development

Table 86. Curia Company Details

Table 87. Curia Business Overview

Table 88. Curia Antibody Drug Conjugate CDMO Product

Table 89. Curia Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 90. Curia Recent Development

Table 91. Novasep Company Details

Table 92. Novasep Business Overview

Table 93. Novasep Antibody Drug Conjugate CDMO Product

Table 94. Novasep Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 95. Novasep Recent Development

Table 96. Ajinomoto Bio-Pharma Services Company Details

Table 97. Ajinomoto Bio-Pharma Services Business Overview

Table 98. Ajinomoto Bio-Pharma Services Antibody Drug Conjugate CDMO Product

Table 99. Ajinomoto Bio-Pharma Services Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 100. Ajinomoto Bio-Pharma Services Recent Development

Table 101. BSP Pharmaceuticals Company Details

Table 102. BSP Pharmaceuticals Business Overview

Table 103. BSP Pharmaceuticals Antibody Drug Conjugate CDMO Product

Table 104. BSP Pharmaceuticals Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 105. BSP Pharmaceuticals Recent Development

Table 106. Cerbios-Pharma Company Details

Table 107. Cerbios-Pharma Business Overview

Table 108. Cerbios-Pharma Antibody Drug Conjugate CDMO Product

Table 109. Cerbios-Pharma Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 110. Cerbios-Pharma Recent Development

Table 111. Goodwin Biotechnology Company Details

Table 112. Goodwin Biotechnology Business Overview

Table 113. Goodwin Biotechnology Antibody Drug Conjugate CDMO Product

Table 114. Goodwin Biotechnology Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)

Table 115. Goodwin Biotechnology Recent Development

Table 116. Research Programs/Design for This Report

Table 117. Key Data Information from Secondary Sources

Table 118. Key Data Information from Primary Sources

Table 119. Authors List of This Report

List of Figures

Figure 1. Antibody Drug Conjugate CDMO Picture

Figure 2. Global Antibody Drug Conjugate CDMO Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Antibody Drug Conjugate CDMO Market Share by Type: 2024 VS 2031

Figure 4. IgG1 Features

Figure 5. IgG4 Features

Figure 6. Global Antibody Drug Conjugate CDMO Market Size by Application (2020-2031) & (US$ Million)

Figure 7. Global Antibody Drug Conjugate CDMO Market Share by Application: 2024 VS 2031

Figure 8. Solid Tumors Case Studies

Figure 9. Hematological Malignancies Case Studies

Figure 10. Antibody Drug Conjugate CDMO Report Years Considered

Figure 11. Global Antibody Drug Conjugate CDMO Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 12. Global Antibody Drug Conjugate CDMO Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global Antibody Drug Conjugate CDMO Market Share by Region: 2024 VS 2031

Figure 14. Global Antibody Drug Conjugate CDMO Market Share by Players in 2024

Figure 15. Global Top Antibody Drug Conjugate CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody Drug Conjugate CDMO as of 2024)

Figure 16. The Top 10 and 5 Players Market Share by Antibody Drug Conjugate CDMO Revenue in 2024

Figure 17. North America Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 18. North America Antibody Drug Conjugate CDMO Market Share by Country (2020-2031)

Figure 19. United States Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. Canada Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. Europe Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Europe Antibody Drug Conjugate CDMO Market Share by Country (2020-2031)

Figure 23. Germany Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. France Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. U.K. Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Italy Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Russia Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Nordic Countries Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Asia-Pacific Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Asia-Pacific Antibody Drug Conjugate CDMO Market Share by Region (2020-2031)

Figure 31. China Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Japan Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. South Korea Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Southeast Asia Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. India Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Australia Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Latin America Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Latin America Antibody Drug Conjugate CDMO Market Share by Country (2020-2031)

Figure 39. Mexico Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Brazil Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Middle East & Africa Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Middle East & Africa Antibody Drug Conjugate CDMO Market Share by Country (2020-2031)

Figure 43. Turkey Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Saudi Arabia Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. UAE Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Lonza Group Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 47. Merck KGaA Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 48. Recipharm Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 49. Thermo Fisher Scientific Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 50. Abbvie Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 51. Piramal Pharma Solutions Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 52. Catalent Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 53. Sterling Pharma Solutions Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 54. Curia Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 55. Novasep Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 56. Ajinomoto Bio-Pharma Services Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 57. BSP Pharmaceuticals Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 58. Cerbios-Pharma Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 59. Goodwin Biotechnology Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Antibody drug Conjugate for Cancer Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Antibody drug Conjugates Market Insights Forecast to 2030

Global ADC Drug CDMO Service Market Research Report 2024

Global Antibody drug Conjugates for Tumors Market Research Report 2024

Global HER2 Antibody Drug Conjugate Market Research Report 2025

Global Antibody drug Conjugate ADC Payload Market Research Report 2025

Global Monoclonal Antibody ADC Drugs Market Research Report 2025

Global Antibody Drug Conjugates Contract Manufacturing Market Research Report 2025

Global ADC Linkers Market Research Report 2024

Antibody Drug Conjugate ADC Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Peptide Drug Conjugates PDCs CDMO Service Market Research Report 2024

Global Antibody Oligonucleotide Conjugates AOC Drug CDMO Market Research Report 2024

Global ADC Manufacturing Service Market Research Report 2025

Global Highly Potent API HPAPI For Antibody drug Conjugate ADC Market Research Report 2025

Global HER2 ADC Drugs Market Research Report 2024

Global Antibody Drug CDMO Service Market Research Report 2024

Global Antibody radionuclide Conjugates Market Research Report 2024

Global Cancer Antibody Drug Conjugates Market Research Report 2024

Global Conjugated Monoclonal Antibodies Market Research Report 2024

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions